Orphazyme A/S (ORPH) Stock Analysis

What Orphazyme A/S does

Orphazyme A/S is a biopharmaceutical entity focused on developing therapeutic interventions for rare neurological conditions. The company's strategy involves amplifying heat-shock proteins to create and commercialize treatments for diseases characterized by protein misfolding and aggregation, as well as lysosomal impairments, which encompass lysosomal storage and neuromuscular degenerative disorders. Their leading experimental drug, Arimoclomol, is currently in clinical development, being investigated for its potential in four distinct orphan diseases: Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis (ALS), Inclusion Body Myositis, and Gaucher disease. Founded in 2009, Orphazyme A/S maintains its headquarters in Copenhagen, Denmark.

Key metrics

ETFs linked to ORPH

Broad-market and Healthcare sector ETFs an investor holding Orphazyme A/S is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ORPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Orphazyme A/S?

Orphazyme A/S trades under the ticker ORPH on NASDAQ.

Which exchange is ORPH listed on?

ORPH is listed on NASDAQ.

What sector does Orphazyme A/S operate in?

Orphazyme A/S is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ORPH in a portfolio?

PortView shows ORPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.